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Abstract
Background: Ductal carcinoma in situ (DCIS) is a non-invasive form of early breast cancer, with a poorly
understood natural history of invasive transformation. Necrosis is a well-recognized adverse prognostic feature of
DCIS, and non-invasive detection of its presence and spatial extent could provide information not obtainable by
biopsy. We describe here imaging of the distribution and extent of comedo-type necrosis in a model of human
DCIS using C2Am, an imaging agent that binds to the phosphatidylserine exposed by necrotic cells.
Methods: We used an established xenograft model of human DCIS that mimics the histopathological features of
the disease. Planar near-infrared and optoacoustic imaging, using fluorescently labeled C2Am, were used to image
non-invasively the presence and extent of lesion necrosis.
Results: C2Am showed specific and sensitive binding to necrotic areas in DCIS tissue, detectable both in vivo and
ex vivo. The imaging signal generated in vivo using near-infrared (NIR) fluorescence imaging was up to 6-fold
higher in DCIS lesions than in surrounding fat pad or skin tissue. There was a correlation between the C2Am NIR
fluorescence (Pearson R = 0.783, P = 0.0125) and optoacoustic signals (R > 0.875, P < 0.022) in the DCIS lesions in vivo
and the corresponding levels of cell death detected histologically.
Conclusions: C2Am is a targeted multi-modal imaging agent that could complement current anatomical imaging
methods for detecting DCIS. Imaging the presence and spatial extent of necrosis may give better prognostic
information than that obtained by biopsy alone.
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Introduction
Breast cancer is the most commonly diagnosed malig-
nancy in women in the Western world, affecting one in
eight women during their lifetime, with approximately
20% of newly diagnosed cases being DCIS [1]. The intro-
duction of mammographic screening programs in the
1980s led to an estimated 40% reduction in breast
cancer-related mortality. However, diagnosis of biologic-
ally indolent breast cancer, which might not otherwise
become clinically apparent during the lifetime of the pa-
tient [2], has led to an estimated overdiagnosis of 10% of
cases, mainly attributed to the sevenfold increase in the
detection rates of DCIS [3].
DCIS is a non-obligate precursor of invasive breast
cancer, representing a pathologically heterogeneous
group of neoplastic processes in situ, with differing
growth rates, a range of microarchitectural and cyto-
logical patterns, and diverse malignant potential, with an
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unpredictable transition time to invasive cancer [3]. Sur-
gical excision is mandatory in the clinical management
of DCIS [4], and while mastectomy offers higher cure
rates, due to its mutilating nature, this has been mostly
replaced by breast-conserving surgery (BCS) [5]. There
is a major clinical concern that the standard-of-care
treatment of DCIS might be unnecessarily aggressive for
patients with lesions deemed as “low risk” [6, 7].
The presence of comedo-type necrosis at diagnosis is
associated with an increased risk of local recurrence,
when BCS is used [8]. Both the presence and the extent
of necrosis within DCIS lesions have been shown, in a
sub-analysis of a large international randomized clinical
trial, to have a significant association with the rates of
both non-invasive and invasive local recurrences [9],
particularly for high-grade lesions [10]. This trial showed
that not only the presence, but also the anatomical ex-
tent of comedo-necrosis holds relevant prognostic infor-
mation [9]. In a recent study, the presence of necrosis in
diagnostic preoperative biopsies of over 600 women with
DCIS was found to be a strong predictor of both DCIS
upgrading and upstaging to invasive carcinoma in the
final surgical specimens [11].
Reliable detection of comedo-type necrosis in biopsy
specimens poses a challenge as it is based on a subjective
assessment and is therefore highly variable [12]. At
present, only post-surgical histological evaluation of
breast resection specimens (lumpectomy or mastectomy)
can reliably determine the actual extent of comedo-type
necrosis. Pre-surgical diagnostic biopsy of suspect DCIS
lesions can only inform on the presence or absence of
this high-risk feature in the spatially limited biopsy spe-
cimen, thus providing potentially incomplete prognostic
information.
The development of novel imaging tools that can pre-
dict prognosis in DCIS more effectively is an unmet clin-
ical need [7]. Current imaging techniques do not provide
prognostic information beyond anatomical estimates of
lesion size, which often lack accuracy when delineating
the extent of DCIS involvement. In the last two decades,
magnetic resonance imaging (MRI) has emerged as a po-
tential adjunct to mammography, despite the additional
cost [13]. However, a meta-analysis concluded that rou-
tine use of preoperative MRI, in addition to conventional
preoperative assessment of patients with newly diag-
nosed DCIS, was not associated with improved surgical
outcomes [14–16]. Recently, the fast hybrid optical and
acoustic technology of optoacoustic (OA) imaging has
emerged as a promising diagnostic tool for the evalu-
ation of breast lesions [17, 18]. To date, the reported OA
trials have focused on imaging tumor hemoglobin con-
centration and oxygenation. While these metrics have
been shown to correlate with tumor necrosis [19], they
do not provide a specific readout of the process. Non-
invasive imaging modalities that can reliably detect and
potentially quantify and map comedo-type necrosis
would be a useful adjunct to mammography.
C2Am is a modified version of the C2A domain of
Synaptotagmin-I, in which a single-cysteine residue, in-
troduced by site-directed mutagenesis, can be used for
selective labeling of the protein with labels detectable
using non-invasive imaging techniques [20]. This small
protein (16 kDa) can detect, with low nanomolar affin-
ity, the phosphatidylserine (PS) externalized to the
outer leaflet of the plasma membrane, during apoptosis,
and which becomes accessible on the inner leaflet of
necrotic cells, following the plasma membrane disrup-
tion that accompanies necrosis [21]. C2Am can detect
tumor cell death following treatment, using fluores-
cence, optoacoustic [22], SPECT [23], and more re-
cently, PET [24] imaging in vivo. We show here that we
can use a fluorophore-labeled derivative of C2Am for
multi-modal detection of comedo-type necrosis with
fluorescence and optoacoustic imaging in an estab-
lished human-in-mouse intraductal transplantation
model of DCIS, which has been shown to model accur-
ately human high-risk DCIS [25].
Materials and methods
Cell culture
All chemicals were obtained from Sigma-Aldrich unless
stated otherwise. MCF10ADCIS.com cells (CVCL_5552,
Asterand, Inc. Detroit, MI) [26, 27] were stably trans-
fected with firefly luciferase and RFP [28] (herein named
MCF10ADCIS), cultured in DMEM/F12 (1:1) medium
supplemented with 5% horse serum (Thermo Fisher Sci-
entific) and 4mM glutamine, in a 37 °C humidified incu-
bator with an atmosphere of 5% CO2. The cell line,
which tested negative for mycoplasma by an RNA cap-
ture ELISA-based method, was genotyped upon arrival
and used within 4 to 8 passages from the original stocks.
An automated cell viability analyzer (Vi-Cell™, Beckman
Coulter) was used to monitor cell number and viability.
Where required, cell death was induced by incubating
cells with 10 μM doxorubicin or 100 μM etoposide
(Teva, Ltd.) for 24 h at 37 °C.
C2Am and iC2Am expression and labeling
For fluorescence and optoacoustic imaging, C2Am and a
site-directed mutant of the protein that no longer binds
to PS (iC2Am) [20] were expressed in E. coli BL21, pre-
viously transformed with pGEX-2T vector containing ei-
ther GST-C2Am or GST-iC2Am [20], purified and
labeled using either DyLight™-650-maleimide (Thermo
Fisher Scientific, Ex/Em = 654/673 nm) for iC2Am or
AlexaFluor™-750-C5-maleimide (Life Sciences, Ex/Em =
750/775 nm) for C2Am. The bioconjugation protocol
has been described previously [20].
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DCIS intraductal murine model
Sub-confluent MCF10ADCIS cells (> 95% viability) were
washed and re-suspended at 5 × 103 cells/mL, in chilled
medium containing 65% DMEM/F12 (1:1), 5% horse
serum, and 20% growth factor-reduced Matrigel (BD
Biosciences). The cell suspension was delivered intraduc-
tally to recipient 8–12-week-old female NOD/SCID-
IL2Rgamma mice (Jackson Laboratories), under isoflurane
(1–3%) anesthesia, using a method described previously
[25]. All animal experiments were performed in compli-
ance with a project license issued under the Animals
(Scientific Procedures) Act of 1986 and were designed
with reference to the UK Co-ordinating Committee on
Cancer Research guidelines for the welfare of animals in
experimental neoplasia [29]. Protocols were approved by
the Cancer Research UK Cambridge Institute Animal
Welfare and Ethical Review Body.
Planar epifluorescence (FLI) and bioluminescence (BLI)
imaging
C2Am and iC2Am were administered as an equimolar
mixture of 0.10 μmol/kg for each of the two probes (10
mL/kg, i.v.). Imaging in vivo and ex vivo was performed
using an IVIS200™ system (Perkin Elmer). BLI was con-
ducted 5–10min following administration of D-luciferin
(Perkin Elmer, 150 mg/kg, i.p. in phosphate-buffered
saline). FLI and BLI were performed under 2–3% isoflur-
ane gas anesthesia mixed with 100% oxygen. Body
temperature was maintained at 37 °C. The in-plane reso-
lution was 100 μm.
Optoacoustic imaging
C2Am (C2Am-AF750) and iC2Am (iC2Am-DyL650)
were administered as an equimolar mixture of
0.20 μmol/kg (10 mL/kg, i.v.). Optoacoustic (OA) im-
aging in vivo was performed using a multispectral optoa-
coustic tomography (MSOT™) inVision 256-TF small
animal imaging system (iThera Medical) [30]. Briefly, a
tunable optical parametric oscillator (OPO) pumped by
a Nd:YAG laser provided excitation pulses with a pulse
width < 7 ns at wavelengths ranging from 660 to 1300
nm at a repetition rate of 10 Hz, wavelength tuning
speed of 10 ms, and peak pulse energy of 90 mJ at 720
nm. Ten arms of a fiber bundle provided uniform illu-
mination of a ring-shaped light strip of approximately 8
mm width, with radiant exposure of < 20 mJ/cm2 (max-
imum permissible exposure) on the sample surface. For
ultrasound detection, 256 toroidally focused ultrasound
transducers, with a center frequency of 5MHz (60%
bandwidth) and organized in a concave array with 270°
angular coverage and a radius of curvature of 4 cm, were
used [31]. Anesthetized animals were wrapped in a thin
polyethylene membrane and placed in the animal holder.
The animal holder was held within the imaging chamber
at a constant temperature (36 °C), maintained by heating
degassed D2O. The mice were allowed to temperature
stabilize for 12 min within the imaging chamber before
any scans were performed. The respiratory rate of the
animals was maintained (70–80 b.p.m.) by modulating
the isoflurane concentration (1.5–2.5% isoflurane
concentration). OA data were acquired from multiple
cross-sectional slices with 10 frame averages. The OA
responses of iC2Am and C2Am were evaluated using
phantoms (Supplementary Figure S2).
Immunohistochemistry and tissue fluorescence imaging
ex vivo
Tissues were fixed for 24 h, using neutral-buffered for-
malin, prior to transfer into 70% ethanol. The sections
(3 μm) were cut using a rotary microtome. Hematoxylin
and eosin (H&E) staining was performed on a Leica
ST5020/CV5030 workstation (Leica Biosystems).
Cleaved-caspase-3 (CC3) and TUNEL staining were per-
formed as described previously [32]. Unstained tissue
sections were de-waxed and rehydrated and the slides
mounted using Prolong Gold™ antifade reagent (Thermo
Fisher Scientific), cured for 24 h at room temperature,
prior to microscopic near-infrared fluorescence (NIRF)
imaging at a resolution of 21 μm, using an Odyssey™ 250
flat-bed scanner (LiCor Inc.).
Statistical analysis
Data are shown as mean ± SD, unless stated otherwise.
A two-tailed Student’s t test was used for pairwise com-
parisons. ANOVA was used for multiple comparisons.
Pearson’s R test was used to assess the significance of
the correlations. P values of < 0.05 were considered sig-
nificant. Statistical analyses were performed in GraphPad
Prism™ (GraphPad Software, vs. 6.0).
Results
The potential of MCF10ADCIS cells to form DCIS-like
lesions was assessed at different time points (2, 5, and
8 weeks, n = 10; Table 1) following intraductal im-
plantation [33]. All lesions, manually identified at
each time point, exhibited high-grade cytonuclear fea-
tures, as determined by hematoxylin and eosin (H&E)
staining (Fig. 1c-e). The DCIS lesion cells contained
pleomorphic, irregularly spaced, and large nuclei,
exhibiting marked variation in size, with irregular
contours, coarse chromatin, and prominent nucleoli.
The co-existence of specific architectural DCIS sub-
types (solid, cribriform, comedo) and invasive carcin-
oma within each lesion was assessed. At 2 weeks
following implantation, cells in DCIS lesions showed
discreet intraductal growth, with no evidence of
necrosis (Fig. 1a). Parallel staining, using antibodies
against a mouse or human proliferation marker (Ki-67,
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brown), and nuclear staining (DAPI, blue) allowed the
identification of human cells within the mouse mammary
ducts (Fig. 1a). Staining of human centromeres (Fig. 1b,
red) confirmed the extrinsic nature of the malignant cell
proliferation. Lesions collected at later time points (5 and
8 weeks following implantation) showed a wider range of
DCIS-specific morphological features, which resembled
those of the human disease (Fig. 1c, d), including cribri-
form (Fig. 1c), solid, and comedo-type (Fig. 1d) lesions,
which coexisted within the same specimen. While 5-week
lesions showed incipient comedo-type necrosis in some (2
in 6) of the xenografts (Table 1), more mature lesions con-
tained a larger number of comedo-type DCIS ducts in all
of the material collected (10 out of 10, Table 1). These
comedo-type lesions consisted of tightly packed tubular
structures with central coagulative necrosis. Closer exam-
ination of H&E-stained sections (Fig. 1c) revealed a dis-
creet basal myoepithelial layer at the periphery of the
duct-like structures. Invasive areas developed in most of
the older lesions (Fig. 1e, arrows; Table 1). Comedo-type
necrosis was evident on H&E staining (Fig. 1e, arrow-
heads) and was identified by the presence of cell ghosts
and its eosinophilic and granular nature. Additional
TUNEL staining detected necrotic cell debris (Fig. 1f,
brown).
We assessed MCF10ADCIS cell death in vitro in order
to establish the capability of C2Am to detect cell death
in this cell line following treatment. Cells were treated
with either doxorubicin or etoposide and cell death was
assessed (Fig. 2) using either an equimolar mixture of
active C2Am and a site-directed mutant that does not
bind PS (iC2Am) [20] or a fluorescent inhibitor of ef-
fector caspases (FLICA [34]). The combined use of
C2Am and iC2Am, which were labeled with two differ-
ent fluorophores, enabled a ratiometric assessment of
cell death that accounted for non-specific probe reten-
tion by the cells (see Supplementary Figure S1). The
level of MCF10ADCIS cell death induced by doxorubicin
(10 μM, 24 h, Fig. 2b, triangles) was higher than that
generated by etoposide (100 μM, 24 h, Fig. 2b, filled cir-
cles), as determined by FLICA staining (Fig. 2a, right).
iC2Am generated low levels of fluorescence (Fig. 2a,
green), which did not correlate (R = 0.124, P = 0.7) with
caspase-3 activation (Fig. 2b). C2Am, however, showed
increased fluorescence with increasing levels of cell
death (Fig. 2a, red), which correlated with the levels of
FLICA staining (Fig. 2c; R = 0.883, P = 0.0001). The
C2Am/iC2Am ratio also correlated with FLICA stain-
ing (R = 0.857, P = 0.0004), with a level of contrast that
Table 1 Morphological features of MCF10ADCIS orthotopic
xenograft lesions
Cohort A B C
Time of tissue harvest post-implantation (weeks) 2 5 8
Number of fat pads injected (N) 4 6 10
Histologically confirmed DCIS/fat pads examined 2/4 6/6 10/10
Tissue architecture of DCIS lesions
Solid 2/2 4/6 2/6
Cribriform 0/2 3/6 2/6
Comedo 0/2 2/6 6/6
Mixed DCIS (at least two types/specimen) 0/2 4/6 2/6
Associated invasive carcinoma 0/2 2/6 4/6
n = 10 mice, 18 lesions
Fig. 1 Histopathological evaluation of an intraductally transplanted
model of DCIS (MCF10ADCIS). Two weeks post-implantation (a, b),
solid-type intraductal growth of MCF10ADCIS cells showed no
staining with an antibody targeted at mouse Ki-67 but positive
staining with an antibody targeted at the human protein (a, brown
stain). DAPI staining (a, b, blue) identified both human and mouse
epithelial cells whereas a FISH probe for human centromeres (b, red)
identified cells of human origin on an autofluorescent (green) tissue
background. Histopathology of DCIS lesions 8 weeks post-
implantation (c, d); cribriform architecture of a MCF10ADCIS xenograft
(c); comedo-type necrosis in a MCF10ADCIS xenograft lesion (d,
arrowheads), with central necrotic areas. Comedo-necrosis type
features of MCF10ADCIS xenografts 8 weeks post-implantation (e, f);
comedo-type DCIS-like (e, arrowheads) and invasive (e, arrows)
structures on H&E; corresponding TUNEL staining (f), showing viable
(gray) and necrotic (brown) regions of tissue. Scale bars = 200 μm (a,
b); 350 μm (c, d); 800 μm (e, f)
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was up to 10-fold higher with C2Am than with iC2Am
(Fig. 2d).
Next, 4 to 8 weeks post-implantation of MCF10ADCIS
orthotopic lesions (n = 10), an equimolar mixture of
C2Am and iC2Am was injected (i.v.) and planar epi-
fluorescence (FLI) and bioluminescence (BLI) images
were acquired at 24 h post-probe administration
(Fig. 3A–C). Representative images acquired in vivo (Fig.
3A1–C1) and ex vivo (Fig. 3A2–C2 and A3–C3) are
shown. The larger (∼ 7 mm) inguinal lesion detected by
BLI (Fig. 3A1, left arrow), was visible in vivo using
C2Am (Fig. 3C1, arrow) but not with iC2Am (Fig. 3B1,
arrow), despite the fluorescence of the two probes being
equivalent (Supplementary Figure S1). Both inguinal le-
sions (Fig. 3A1, arrows, BLI) were visible ex vivo using
C2Am (Fig. 3C2, arrows) but not with iC2Am (Fig. 3B2,
arrows). C2Am fluorescence-guided resection of the lar-
ger lesion (Fig. 3C1, left arrow and C3, left) showed ca.
3-fold greater (lesion/fat pad) contrast ex vivo with
C2Am than with iC2Am (Fig. 3F, red symbols). Overall,
lesions showed significantly higher levels (ca. 7-fold, P <
0.005) of fluorescence in vivo (Fig. 3D) with C2Am than
with iC2Am. The relative increase in C2Am fluorescence
in vivo in fat pad tissue was also significantly higher, in
comparison with iC2Am, albeit the contrast was much
lower than that observed for lesion tissue (Fig. 3E, ca.
1.5-fold, P < 0.005). The lesion-to-fat pad contrast
in vivo was also ca. 3-fold higher (Fig. 3F, P < 0.005,),
using the active C2Am probe. Moreover, the ratiometric
(C2Am/iC2Am) assessment of cell death in vivo corre-
lated (Fig. 3G, R = 0.783, P = 0.0125) with the assessment
of lesion cell death ex vivo using the TUNEL staining
assay. Subsequent histochemical assessment of excised
lesion sections (Fig. 4) showed good co-localization of
the ratiometric C2Am/iC2Am signal (Fig. 4c) with lesion
cell death detected by TUNEL staining (Fig. 4b), for the
two lesions present in this mouse (Fig. 3A1).
Next, we analyzed multiple excised lesion sections
from a cohort of animals (n = 10), 4 to 8 weeks following
intraductal implantation of MCF10ADCIS cells. H&E
staining (Fig. 5a, top left) of representative lesions
showed clear ductal lesion structures (L) embedded in
Fig. 2 Detection of MCF10ADCIS cell death in vitro using C2Am. Cells were treated with chemotherapeutic drugs (doxorubicin or etoposide) and
incubated with either an equimolar mixture of C2Am|iC2Am or with a fluorescent inhibitor of effector caspases (FLICA) as a reference gold
standard. Plates (a) were scanned at different excitation/emission wavelengths: iC2Am (650/680 nm), C2Am (780/800 nm), and FLICA (450/480
nm). Correlations of iC2Am staining (b), C2Am staining (c), and the ratio C2Am/iC2Am (d) with FLICA staining. UT-untreated (open circles), DOX-
doxorubicin (inverted triangles), and ETP-etoposide-treated (filled circles) cells. C2Am and iC2Am were labeled with DyLigh-750 and AlexaFluor-
650, respectively (see Supplementary Figure S1 and Methods). FLICA-fluorescent inhibitor of effector caspases. n = 4 technical replicates per
experimental condition, 2 independent experiments
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fat pad tissue (fp) and surrounded by skin (sk). Within
these lesions, there were areas with variable cell prolifer-
ation (Fig. 5a, Ki-67-stained). Defined, punctate areas of
necrosis visible in the lesions (Fig. 5a, H&E) were also
detected by cleaved caspase-3 (Fig. 5a, CC3) and TUNEL
(Fig. 5a, TUNEL) staining. In regions of interest (ROI)
within these lesions, the ratiometric C2Am/iC2Am sig-
nal showed a strong correlation (R = 0.717, P = 0.0012)
with TUNEL staining (Fig. 5a, ROI analysis). A correl-
ation was also found between the ratiometric C2Am/
iC2Am signal and TUNEL staining for a large panel of
lesions (Fig. 5b, lesion) but not for fat pad (Fig. 5b, fat
pad) or skin (Fig. 5b, skin). The contrast obtained with
the ratiometric C2Am/iC2Am signal (Fig. 5c, left) was
also significantly greater for lesions, in comparison with
surrounding fat pad (30-fold, P < 0.0001) and skin (15-
fold, P < 0.0001), and increased in proportion to the
levels of cell death detected by TUNEL staining in those
lesions (Fig. 5c, L1–L4).
Lastly, with a view to clinical translation, we con-
ducted optoacoustic imaging of cell death in the same
DCIS model using C2Am and iC2Am. Six to 8 weeks
post-orthotopic implantation of MCF10ADCIS cells, an
equimolar mixture of C2Am and iC2Am was injected
(i.v.) and optoacoustic imaging (Fig. 6a, b) and FLI (Fig.
6c) were performed in vivo and ex vivo, respectively, at 4
and 24 h post-probe administration. There were strong
correlations between C2Am lesion MSOT signal and cell
death markers (Fig. 6d), CC3 (Fig. 6d, R = 0.973, P =
0.001), and TUNEL (Fig. 6d, R = 0.962, P = 0.002) and
Fig. 3 Fluorescence imaging of native cell death in the MCF10ADCIS model of human DCIS. Bioluminescence (BLI, A) and epifluorescence images
(FLI; B, C) of a representative mouse implanted intraductally with MCF10ADCIS cells. Four to 8 weeks post-implantation, lesions (black arrows) were
visible in vivo by BLI (A) and the larger lesion by FLI of C2Am in vivo (C1, arrow) and both lesions ex vivo (C2, arrows), but neither were visible by
FLI of iC2Am in vivo (B1, arrow) or easily distinguishable ex vivo (B2, arrows). Lesion (D), fat pad (E), and lesion/fat pad ratios (F) of mean
fluorescence intensity (MFI) were calculated for C2Am and iC2Am. The C2Am/iC2Am MFI ratio was also calculated for lesions and correlated with
the levels of cell death, quantified by TUNEL staining of excised lesion sections (G). The images ex vivo (A–C: 2, 3) show the two lesions in situ in
the mouse (A2, B2, C2, arrows) and the same lesions post-resection (A3, B3, C3) on a plate. Wilcoxon matched-pair analysis, red and blue dots
(D–G) correspond to imaging data shown in (A–C), for left-side (red) and right-side (blue) lesions. **P < 0.005 (D–F). n = 5 mice, 9 lesions
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also between C2Am lesion MSOT and FLI signals (Fig.
6d, R = 0.875, P = 0.022). iC2Am lesion MSOT and FLI
signals (Fig. 6d) did not correlate with the cell death
markers.
Discussion
Several cell surface markers have been proposed as
targets for the molecular imaging of DCIS, including
IGF1-R, VEGFr, HER2, EGFR, MET, CD44v6, GLUT1,
CA-XII, and mammaglobin [35]. However, to date,
none of these biomarkers has been generally adopted
as a predictor of DCIS recurrence [36]. Fluorescence
imaging of CA-IX, a marker of hypoxia, has been
suggested for better delineation of DCIS margins at
surgery [37]. However, hypoxia lacks specificity as a
marker of DCIS, since it can be a feature of any
highly proliferative process, either benign or malig-
nant [38], particularly in breast ducts.
Molecular markers, including hormone receptors
(estrogen or progesterone) and HER-2 expression status,
have been used previously as imaging biomarkers of
breast cancer [39, 40]. However, these breast cancer
biomarkers have not been established as prognostic fea-
tures of DCIS [41], despite their clinical relevance as
prognostic factors in breast cancer [42]. In contrast, ne-
crosis is a highly specific, pathognomonic feature of
DCIS, present in up to 93% of all DCIS cases [38, 43]
and rarely exhibited (< 3%) by other benign or high-risk
proliferative conditions of the breast [44], and which has
been used as a prognostic marker of DCIS for several
decades [45]. The UKCCCR/ANZ DCIS trial demon-
strated that not only the presence but also the anatom-
ical extent of DCIS-associated necrosis are adverse
prognostic features of the disease, and both are strong
predictors of invasive recurrence [9]. Moreover, in a 10-
year follow-up study of 728 patients, the presence of
confluent tumor necrosis in invasive areas of lymph-
node positive breast cancer, within 2 years of diagnosis,
was found to be an independent predictor for early re-
currence and overall survival [46].
Owing to the significant concern of overdiagnosis
and associated overtreatment, there are several on-
going clinical trials exploring treatment de-escalation
in the management of DCIS [47, 48]. These trials
compare active patient surveillance with the current
standard of care (mandatory surgical excision) and
have excluded patients with DCIS harboring adverse
prognostic features, including the presence of com-
edo-necrosis at biopsy. However, reliable detection of
comedo-type necrosis in biopsy specimens shows sig-
nificant variability, even among expert pathologists
[12]. Moreover, segments of DCIS containing the
comedo sub-type can be potentially missed, since a
single biopsy cannot be informative of the extent of
DCIS present in the entire network of breast ducts.
Approximately 10% of patients, deemed eligible as
“low risk” DCIS for the ongoing COMET, LORD, and
LORIS trials based on the initial diagnostic biopsy,
have been estimated to belong to the “high-risk”
group [9].
To our knowledge, the use of DCIS-associated ne-
crosis as an imaging biomarker of the diseased breast
has not yet been explored. Non-invasive molecular
imaging of comedo-type necrosis could serve as an
adjunct modality in the selection of patients for active
surveillance. Moreover, it could also provide comple-
mentary prognostic information on the extent of ag-
gressive, high-risk disease that cannot be obtained by
biopsy.
Annexin-V (35 kDa) is a PS-binding protein that
has been tested in the clinic as a cell death imaging
agent. However, it showed suboptimal contrast and
unfavorable pharmacokinetics [49]. We have used
here C2Am, a smaller (16 kDa) cell death imaging
agent, which also detects PS exposure, to detect
comedo-type necrosis in DCIS in a well-characterized
Fig. 4 Immunohistochemistry of MCF10ADCIS lesions. Representative
sections from the two lesions (left and right side, respectively)
resected from the mice shown in Fig. 3a-c, H&E (a); TUNEL (b), and
C2Am/iC2Am ratiometric fluorescence image (c). L, lesion; fp, fat
pad; sk, skin. Scale bars = 1.0 mm
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human-to-mouse xenograft model (Fig. 1). The probe
was used in combination with an inactive counterpart
(iC2Am) and showed high specificity for detecting cell
death in vitro (Fig. 2), in vivo (Figs. 3 and 6), and
ex vivo (Fig. 4). Moreover, C2Am demonstrated high
sensitivity for detecting the relatively low levels of cell
death present in MCF10ADCIS lesions (< 5%) in vivo
(Fig. 3g) and ex vivo (Fig. 4) and over a wide dynamic
range (up to 20% in vivo, Fig. 3g, and up to 80%
ex vivo, Fig. 5a). High levels of contrast were ob-
tained for lesion/fat pad (30-fold) and lesion/skin (15-
fold) (Fig. 5c, left), and the ratiometric C2Am/iC2Am
signal was shown to correlate with the levels of cell
death (Fig. 5c, right) detected by TUNEL staining.
Recent reports using optoacoustic techniques have
demonstrated the capabilities of the technique for breast
imaging [18]. We showed that the signal obtained from
C2Am (Fig. 6a, b) using multispectral optoacoustic tom-
ography (MSOT) correlated well with that obtained
using fluorescence imaging (Fig. 6c, top). Moreover, the
C2Am MSOT signal also correlated well with histo-
logical markers of cell death, CC3, and TUNEL (Fig. 6d),
Fig. 5 Immunohistochemistry of MCF10ADCIS lesions. Serial histological sections (a) of one representative MCF10ADCIS lesion resected 8 weeks
post-intraductal cell implantation. H&E, Ki-67, CC3, TUNEL, and C2Am/iC2Am ratiometric fluorescence signals are shown. Chart (a), correlation of
the C2Am/iC2Am ratiometric signal with the percentage of cell death, determined by TUNEL assay, for regions of interest (ROI) of the lesion
shown in a. L, lesion; fp, fat pad; sk, skin. Correlation of C2Am/iC2Am ratiometric signal (b) from multiple lesions, fat pad, and skins from several
mice with the corresponding levels of TUNEL staining. C2Am/iC2Am ratiometric signal (c) in multiple fat pad, skin, and lesions. L1: < 10% TUNEL
positivity, L2: 10–25%, L3: 25–50%, L4: > 50%. b, c, n = 10 mice, 89 lesions, 22 fat pad, 17 skin samples. c Two-tailed, t test, unequal variance. **P <
0.005, ***P < 0.001, ****P < 0.0001. Scale bars (a) = 2 mm
Szucs et al. Breast Cancer Research           (2021) 23:25 Page 8 of 11
whereas iC2Am generated significantly less signal
(P < 0.05, n = 6) in the same lesions (Fig. 6d). Beyond
wide-field epi-illumination fluorescence imaging,
optoacoustic methods can offer high-resolution and
cross-sectional imaging at several centimeters depth
[17]. C2Am-based imaging of cell death using optoa-
coustic imaging could bring additional prognostic
value to DCIS imaging, complementing mammog-
raphy and other anatomical imaging modalities, which
could prove particularly beneficial for the secondary
surveillance of women with an increased risk of
breast cancer [50]. Optoacoustic imaging is a bed-side
technique that could provide a faster and cheaper
diagnostic method than MRI.
Conclusions
Clinical translation of C2Am for imaging the presence
and spatial extent of necrosis in DCIS may provide valu-
able prognostic information that is not obtainable from
biopsy alone.
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The online version contains supplementary material available at https://doi.
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Additional file 1: Figure S1 Fluorescence imaging (a) of C2Am and
iC2Am standard solutions. Excitation (dashed) and emission (filled)
profiles (b) of iC2Am-650 (Ex/Em: 652|672 nm, red, left) and C2Am-750
(Ex/Em: 753|783 nm, brown, right). Serial dilutions (decreasing concentra-
tion, left to right) of the imaging probes (c, e) were imaged on an
Fig. 6 Multi-modal imaging of native cell death in the MCF10ADCIS model of human DCIS. Two lesions were implanted in the lower mammary
glands of three mice. Time series of axial optoacoustic images of C2Am and iC2Am, at the level of the lesion (a, top), and kidneys (a, bottom) in
a representative animal. Time courses of optoacoustic (MSOT) signal in the two lesions are shown (b). Fluorescence imaging (FLI) ex vivo (c, top)
of histological sections of the lesions shown in a. Histological sections (c, bottom) of lesions in a stained for CC3 and TUNEL; areas of staining
(orange/brown) are highlighted against background signal (blue); level of cell death in the lesion is shown (lower right, %). Pearson correlation
analyses (d) of C2Am and iC2Am optoacoustic signals with CC3 and TUNEL staining, of C2Am and iC2Am optoacoustic signals with the
corresponding fluorescence signals, and of TUNEL staining with CC3 staining. Open circles (C2Am); closed circles (iC2Am). n = 3 mice, 6 lesions.
Scale bars (a, b) = 10 mm, (c, d) = 4 mm. Dashed lines (a, top) indicate lesion location
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IVIS200™ system and the mean fluorescence intensity (in radiant effi-
ciency) correlated with probe concentration, in the far red (d) and near
infra-red NIR (f), for C2Am (open circles) and iC2Am (closed squares).
iC2Am fluorescence (d) in the far-red (black squares) was minimal (ca.
10% of that of C2Am, open circles). C2Am fluorescence (f) in the NIR was
undetectable. Fluorescence intensities (g) of C2Am-650 (in the far-red,
open circles in g, data in 2nd row of c) and iC2Am-750 (in the NIR, closed
squares in g, data in the top row of e) were identical at all concentra-
tions. A 1:1 molar mixture (h) of C2Am|iC2Am (c, e, lower row) was also
imaged in the far-red (open circles) and NIR (closed squares) showing
equivalent readouts at all concentrations, in the range 40-2,500 nM. Fig-
ure S2. Single wavelength OA images of (a) phantoms (b) and in vivo
tumor models are illustrated with the regions of interest (ROIs) used for
the data analysis outlined. (c) OA spectra of iC2Am and C2Am molecules
were obtained from multispectral imaging of the probes using tissue
mimicking phantoms.
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